SCHEMBL26969752

SCHEMBL26969752

O=S(=O)(NC1CCC2(CC1)CN(S(=O)(=O)c1ccc(C(F)F)cc1)c1ccccc12)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
HTT P42858 4/20 0.47
LMNA P02545 3/20 0.47
GAA P10253 3/20 0.47
TSHR P16473 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
PKM P14618 2/20 0.47
MAPT P10636 1/20 0.45
HCRTR1 O43613 1/20 0.45
XBP1 P17861 1/20 0.39
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
NPY5R Q15761 1/20 0.38
ACLY P53396 1/20 0.37
KDM4E B2RXH2 2/20 0.36
POLB P06746 1/20 0.36
DRD2 P14416 1/20 0.36
ADRA1D P25100 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26969737 0.86 NPY5R (0.42) ALDH1A1MEN1KMT2ANPY5RACLY
SCHEMBL30733398 0.83 ACLY (0.43) MEN1KMT2ANPY5RACLYCYP3A4
SCHEMBL25274228 0.82 NPY5R (0.46) ALDH1A1SMN1; SMN2LMNANPY5RACLY
SCHEMBL30733427 0.82 ACLY (0.42) TSHRMEN1KMT2ANPY5RACLY
SCHEMBL25237936 0.81 ACLY (0.41) MEN1KMT2ANPY5RACLYCYP3A4
SCHEMBL26969776 0.81 ACLY (0.41) MEN1KMT2ANPY5RACLYCYP3A4
SCHEMBL26969781 0.81 EPHX1 (0.44) MEN1KMT2AMAPTNPY5RCYP3A4
SCHEMBL30733425 0.80 CYP3A4 (0.43) ALDH1A1SMN1; SMN2TSHRNPY5RACLY
SCHEMBL25237931 0.80 ACLY (0.41) ALDH1A1MEN1KMT2AMAPTNPY5R
SCHEMBL25239332 0.79 NPY5R (0.47) NPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416262-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416262-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 ALDH1A1 3737/4885SMN1; SMN2 1776/4885HTT 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.